Truist Securities Maintains Buy on Allogene Therapeutics, Lowers Price Target to $18
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Asthika Goonewardene maintains a 'Buy' rating on Allogene Therapeutics (NASDAQ:ALLO), but has lowered the price target from $20 to $18.
July 12, 2023 | 3:31 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Allogene Therapeutics' price target has been lowered from $20 to $18 by Truist Securities, though the 'Buy' rating is maintained.
The news is directly related to Allogene Therapeutics and is likely to influence investor sentiment. While the 'Buy' rating is maintained, the lowering of the price target may create some uncertainty among investors, potentially impacting the stock's short-term performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100